AU2013335678B9 - Therapeutic agent for amyotrophic lateral sclerosis - Google Patents

Therapeutic agent for amyotrophic lateral sclerosis Download PDF

Info

Publication number
AU2013335678B9
AU2013335678B9 AU2013335678A AU2013335678A AU2013335678B9 AU 2013335678 B9 AU2013335678 B9 AU 2013335678B9 AU 2013335678 A AU2013335678 A AU 2013335678A AU 2013335678 A AU2013335678 A AU 2013335678A AU 2013335678 B9 AU2013335678 B9 AU 2013335678B9
Authority
AU
Australia
Prior art keywords
amino acid
ghrelin
therapeutic agent
acid residue
lateral sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013335678A
Other languages
English (en)
Other versions
AU2013335678A1 (en
AU2013335678B2 (en
Inventor
Mayumi Furuya
Tsuyoshi Matsuo
Norihito Murayama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of AU2013335678A1 publication Critical patent/AU2013335678A1/en
Application granted granted Critical
Publication of AU2013335678B2 publication Critical patent/AU2013335678B2/en
Publication of AU2013335678B9 publication Critical patent/AU2013335678B9/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
AU2013335678A 2012-10-24 2013-10-23 Therapeutic agent for amyotrophic lateral sclerosis Active AU2013335678B9 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012-234300 2012-10-24
JP2012234300 2012-10-24
PCT/JP2013/078743 WO2014065341A1 (ja) 2012-10-24 2013-10-23 筋萎縮性側索硬化症治療剤

Publications (3)

Publication Number Publication Date
AU2013335678A1 AU2013335678A1 (en) 2015-05-21
AU2013335678B2 AU2013335678B2 (en) 2017-10-26
AU2013335678B9 true AU2013335678B9 (en) 2024-12-12

Family

ID=50544716

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013335678A Active AU2013335678B9 (en) 2012-10-24 2013-10-23 Therapeutic agent for amyotrophic lateral sclerosis

Country Status (11)

Country Link
US (1) US20150265680A1 (https=)
EP (1) EP2913063B1 (https=)
JP (1) JP6262661B2 (https=)
KR (3) KR102499918B1 (https=)
CN (2) CN110354265A (https=)
AU (1) AU2013335678B9 (https=)
BR (1) BR112015009107A2 (https=)
CA (1) CA2889499C (https=)
IN (1) IN2015DN04172A (https=)
RU (1) RU2655811C2 (https=)
WO (1) WO2014065341A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201703884PA (en) 2014-11-12 2017-06-29 Lyric Pharmaceuticals Inc Treatment of enteral feeding intolerance
WO2017083882A1 (en) * 2015-11-11 2017-05-18 Lyric Pharmaceuticals Inc. Treatment of enteral feeding intolerance and other conditions using ulimorelin analogs
MA54383A (fr) * 2018-12-06 2021-10-13 Biogen Ma Inc Protéine neurofilamenteuse pour guider une intervention thérapeutique dans la sclérose laterale amyotrophique
KR20250107210A (ko) * 2022-11-03 2025-07-11 루모스 파마, 인크. 이부타모렌의 압축형 경구 제형

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1258250A1 (en) * 1999-12-28 2002-11-20 Kaken Pharmaceutical Co., Ltd. Nerve protective drugs
WO2006079077A2 (en) * 2005-01-20 2006-07-27 Acadia Pharmaceuticals Inc. Use of diltiazem or analogs thereof as modulators of ghrelin receptor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668254A (en) 1990-05-11 1997-09-16 Romano Deghenghi D-2-alkyl-tryptophan and peptides containing same
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5536716A (en) 1992-12-11 1996-07-16 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
CA2340701C (en) 1998-08-20 2009-05-26 Sumitomo Pharmaceuticals Co., Ltd. Oxindole derivatives as growth hormone releasers
KR100827973B1 (ko) * 1999-07-23 2008-05-21 겐지 간가와 신규 펩티드
UA73530C2 (uk) 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
AR029941A1 (es) 2000-06-13 2003-07-23 Zentaris Gmbh Compuestos utiles para elevar el nivel plasmatico de la hormona del crecimiento y las composiciones farmaceuticas que las contienen
WO2003084983A1 (en) 2002-04-11 2003-10-16 Daiichi Suntory Pharma Co., Ltd. Process for producing modified peptide
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
JP2005239712A (ja) 2004-01-30 2005-09-08 Kaken Pharmaceut Co Ltd 神経突起伸展剤
US7829589B2 (en) 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
CA2625341A1 (en) * 2005-10-18 2007-04-26 Ono Pharmaceutical Co., Ltd. Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis
WO2007146046A2 (en) 2006-06-07 2007-12-21 Genzyme Corporation Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
JP2008127377A (ja) 2006-11-24 2008-06-05 Jichi Medical Univ Ｇｈｓ−ｒ作動薬を含有してなるメタボリックシンドローム又は高血圧症の予防・治療剤。
KR100946084B1 (ko) 2008-03-27 2010-03-10 주식회사 하이닉스반도체 반도체 소자의 수직형 트랜지스터 및 그 형성방법
MX2010010495A (es) * 2008-04-03 2010-10-15 Hoffmann La Roche Uso de variantes del factor de crecimiento similar a la insulina (igf-i) pegiladas para el tratamiento de trastornos neuromusculares.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1258250A1 (en) * 1999-12-28 2002-11-20 Kaken Pharmaceutical Co., Ltd. Nerve protective drugs
WO2006079077A2 (en) * 2005-01-20 2006-07-27 Acadia Pharmaceuticals Inc. Use of diltiazem or analogs thereof as modulators of ghrelin receptor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
B. HOLST ET AL, "Overlapping Binding Site for the Endogenous Agonist, Small-Molecule Agonists, and Ago-allosteric Modulators on the Ghrelin Receptor", MOLECULAR PHARMACOLOGY, US, (20090101), vol. 75, no. 1, pages 44 - 59 *
DIANA GARCIA DEL BARCO ET AL: "Therapeutic Effect of the Combined Use of Growth Hormone Releasing Peptide-6 and Epidermal Growth Factor in an Axonopathy Model", NEUROTOXICITY RESEARCH, vol. 19, no. 1, 19 February 2010 , pages 195-209 *
LEE S ET AL., "Ghrelin protects spinal cord motoneurons against chronic glutamate excitotoxicity by inhibiting microglial activation", KOREAN J PHYSIOL PHARMACOL, (201202), vol. 16, no. 1, pages 43 - 8 *

Also Published As

Publication number Publication date
JPWO2014065341A1 (ja) 2016-09-08
BR112015009107A2 (pt) 2017-11-14
CA2889499A1 (en) 2014-05-01
RU2015119472A (ru) 2016-12-20
JP6262661B2 (ja) 2018-01-17
AU2013335678A1 (en) 2015-05-21
KR20220051418A (ko) 2022-04-26
KR20200108494A (ko) 2020-09-18
RU2655811C2 (ru) 2018-05-29
CA2889499C (en) 2019-09-10
WO2014065341A1 (ja) 2014-05-01
EP2913063A4 (en) 2016-07-20
AU2013335678B2 (en) 2017-10-26
CN104853778A (zh) 2015-08-19
US20150265680A1 (en) 2015-09-24
CN110354265A (zh) 2019-10-22
HK1214152A1 (en) 2016-07-22
KR102499918B1 (ko) 2023-02-14
KR20150070180A (ko) 2015-06-24
EP2913063B1 (en) 2019-09-11
EP2913063A1 (en) 2015-09-02
IN2015DN04172A (https=) 2015-10-16

Similar Documents

Publication Publication Date Title
JP6552117B2 (ja) 敗血症の予防治療剤
JP5956664B2 (ja) 脂肪異栄養症の処置
EP0309100B1 (en) Use of amylin or CGRP for the treatment of diabetes mellitus
EP3393496B1 (en) Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions
CN115124602B (zh) Gip和glp-1的双受体激动剂、药物组合物及用途
AU2013335678B9 (en) Therapeutic agent for amyotrophic lateral sclerosis
KR20200038408A (ko) IF1 (ATPase inhibitory factor 1)을 유효성분으로 함유하는 근감소증의 예방 또는 치료용 약학 조성물
TW201321403A (zh) 藉由Ｋｖ１．３鉀通道之藥物標靶治療肥胖及肥胖相關疾病
WO2024027553A1 (zh) 一种双功能融合蛋白及其用途
HK1214152B (en) Therapeutic agent for use in treating amyotrophic lateral sclerosis
EP2790703B1 (en) Samidorphan (alks 33) in combination with opioid agonists
RU2721282C2 (ru) Способ лечения рассеянного склероза (варианты)
EP4017870B1 (en) Compositions and methods for treating and preventing autoimmune induced cardiac long qt syndrome
US20250161255A1 (en) New therapy and prevention for suppressing aging-related disorders including sarcopenia
US20080125360A1 (en) Composition Comprising Pyy for the Treatment of Gastrointestinal Disorders
JP2007538017A (ja) 胃腸疾患の治療のためのｐｐｙ含有組成物
US11028141B2 (en) Therapeutic for the prevention and/or treatment of weight gain and/or diabetes
EP4656652A1 (en) Novel brain disease therapeutic and use thereof
WO2026056985A1 (zh) 抑郁症的治疗方法和药物组合物
WO2023245543A1 (en) Uses of fgf21 fusion proteins
CN101128213A (zh) 胰腺β细胞再生的促进剂以及在胰腺β细胞中生产胰岛素的促进剂
HK1197180B (en) Samidorphan (alks 33) in combination with opioid agonists
HK1000934B (en) Use of amylin or cgrp for the treatment of diabetes mellitus

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
ROP Revocation of patent

Effective date: 20241122

SREP Specification republished